Unlock instant, AI-driven research and patent intelligence for your innovation.
Application of remdesivir in the preparation of cardiotoxic drugs for the treatment of anti-tumor drugs
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology of therapeutic effects and drugs, applied in the field of biomedicine, can solve problems such as heart damage and toxicity enhancement, and achieve the effect of improving application potential and market prospects
Active Publication Date: 2022-01-11
北京箭牧科技有限公司
View PDF3 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
Cardiotoxicity caused by anthracyclines is usually progressive and irreversible, and may cause cardiac damage on initial use
At the same time, the cardiotoxicity of anthracyclines is also closely related to the involved dose. For example, single high-dose medication, mediastinal radiotherapy, and combined use with cyclophosphamide, trastuzumab, and taxanes can all increase toxicity
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0031] Example 1 Remdesivir effectively inhibits acute death caused by tumor drugs
[0034] 2. Remdesivir: Protect from light, seal, and dry at 4°C. Take an appropriate amount of medicine, dissolve it in 0.5% sodium carboxymethylcellulose, and make it 8mg / mL (relative to 80mg / kg). The 8mg / mL solution was diluted serially. Each animal was orally given 0.2mL / 20g by gavage according to body weight. Ready to use.
[0069] Example 2 Remdesivir has cardioprotective effect against the cardiotoxicity of anti-tumor drugs
[0070] 1. Experimental materials
[0071] With embodiment 1.
[0072] 2. Experimental group
[0073] With embodiment 1.
[0074] 3. Experimental steps
[0075] 1. Construct the ADM-induced mouse model and start to treat with different concentrations of remdesivir on the same day, and administer it continuously orally.
[0076] 2. Mice with a cumulative toxicity of 20 mg / kg underwent echocardiography after the 10th day of treatment with Remdesivir, and mice with a cumulative toxicity of 18 mg / kg underwent echocardiography after the 24th day of treatment with Remdesivir to detect changes in cardiac function in the mice , and perform data analysis.
[0077] 4. Experimental method
[0078] 1. Echocardiographic detection: put the mice in the pre-sedation chamber, use 3% isoflurane, 1000mL / min to induce anesthesia, take the mouse out of the pre-session chamber after the rig...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
PUM
Login to View More
Abstract
The invention discloses the application of Remdesivir in the preparation of cardiotoxic drugs for treating anti-tumor drugs. The present invention confirms the great potential of remdesivir as a cardiotoxic drug that inhibits tumor drugs, discloses for the first time the good curative effect of remdesivir on cardiotoxicity caused by anti-tumor drugs, and provides an effective new treatment for cardiotoxicity of anti-tumor drugs. Potential drug candidates have expanded the indications of Remdesivir and greatly improved the application potential and market prospects of Remdesivir.
Description
technical field [0001] The present invention relates to the field of biomedicine, in particular to the application of remdesivir in the treatment of antitumor drugcardiotoxicity and myocardial protection. Background technique [0002] Remdesivir (RDV, GS-5734) is a nucleoside analog antiviral drug developed by Gilead Sciences (GILD) that works by inhibiting viral nucleic acid synthesis. [0003] In the patent WO2009132123A1, the general formula of the compound structure of Remdesivir was proposed for the first time, which is used for the treatment of hepatitis C virus infection, dengue fever and other flaviviridaevirus infection diseases. Patent WO2012012776A1 proposes the effect of Remdesivir in treating diseases infected by Paramyxoviridae viruses. In subsequent patents, it is also proposed that RDV can be used as an anti-filovirus, anti-arenavirus and anti-coronavirus drug. According to the literature information, the anti-tumor drug cardiotoxicity inhibitory effect o...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to View More 
Login to View More